Dutas long term study
Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
OBJECTIVES:: Dutas, a dual inhibitor of Type 1 and Type 2 5alpha-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutas.
METHODS:: Patients randomised to dutas or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutas 0.5mg daily (dutas/dutas [D/D] group and placebo/dutas [P/D group]). RESULTS:: Significant improvements in AUA-SI score and Q(max) were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q(max), and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutas.
CONCLUSIONS:: Long-term treatment with dutas results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutas was also well tolerated in long-term use.
Regrowth Notes: Although this study does not deal directly with hair loss, it does show that Dutas is well tolerated and remains effective at reducing DHT over a long periods of time.
(Dutas=Dutasteride).
Che ne dite raga?
Io ho incominciato da giovedì a prendere l'avodart una cps ogni 3 giorni.Vengo da un 1 anno e mezzo di fina:caduta arrestata e pochi sides.Che ne dite della posologia,va bene secondo voi?A me l'ha consigliata il dott. Marliani,dove sono in cura.
Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
OBJECTIVES:: Dutas, a dual inhibitor of Type 1 and Type 2 5alpha-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutas.
METHODS:: Patients randomised to dutas or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutas 0.5mg daily (dutas/dutas [D/D] group and placebo/dutas [P/D group]). RESULTS:: Significant improvements in AUA-SI score and Q(max) were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q(max), and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutas.
CONCLUSIONS:: Long-term treatment with dutas results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutas was also well tolerated in long-term use.
Regrowth Notes: Although this study does not deal directly with hair loss, it does show that Dutas is well tolerated and remains effective at reducing DHT over a long periods of time.
(Dutas=Dutasteride).
Che ne dite raga?
Io ho incominciato da giovedì a prendere l'avodart una cps ogni 3 giorni.Vengo da un 1 anno e mezzo di fina:caduta arrestata e pochi sides.Che ne dite della posologia,va bene secondo voi?A me l'ha consigliata il dott. Marliani,dove sono in cura.
][